Listed

Nanobiotix S.A.: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Apr 24, 2024 and accepted by EDGAR at Apr 24, 2024, 16:23 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31EUR 36.2mifrs-full:Revenue
Operating income12 months2023-01-01 to 2023-12-31−EUR 26.8mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31EUR 120.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31−EUR 39.7mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2023-01-01 to 2023-12-31−EUR 1.08ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-01-01 to 2023-12-31−EUR 1.08ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31−EUR 12.5mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31EUR 328.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2023-12-31EUR 75.3mifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31EUR 87.3mifrs-full:CurrentAssets
Total assetsAt period end2023-12-31EUR 93.9mifrs-full:Assets
Current liabilitiesAt period end2023-12-31EUR 49.9mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2023-12-31−EUR 1.8mifrs-full:Equity
Shares outstandingAt period end2023-12-3147,133,328 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001760854-24-000004. Last ingested by Listed: Oct 26, 2026, 06:02 ET. Listed shows no prices and gives no investment advice.